These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22711347

  • 1. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
    Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2007 Aug; 50(1):16-23. PubMed ID: 17164553
    [Abstract] [Full Text] [Related]

  • 3. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [Abstract] [Full Text] [Related]

  • 4. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
    Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    Intervirology; 2013 Jun; 56(1):13-21. PubMed ID: 22907167
    [Abstract] [Full Text] [Related]

  • 5. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
    [Abstract] [Full Text] [Related]

  • 6. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [Abstract] [Full Text] [Related]

  • 7. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
    Ogura S, Akuta N, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    Intervirology; 2009 Apr; 52(4):179-88. PubMed ID: 19546575
    [Abstract] [Full Text] [Related]

  • 8. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2004 Apr; 47(6):355-61. PubMed ID: 15564748
    [Abstract] [Full Text] [Related]

  • 9. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF.
    Antivir Ther; 2006 Apr; 11(8):985-94. PubMed ID: 17302368
    [Abstract] [Full Text] [Related]

  • 10. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M, Ken A, Okuno T.
    Cancer; 1999 May 01; 85(9):1943-50. PubMed ID: 10223234
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.
    J Gastroenterol Hepatol; 2005 May 01; 20(5):752-8. PubMed ID: 15853990
    [Abstract] [Full Text] [Related]

  • 12. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.
    Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O.
    J Hepatol; 2010 Jan 01; 52(1):72-8. PubMed ID: 19910070
    [Abstract] [Full Text] [Related]

  • 13. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2008 Aug 01; 80(8):1354-62. PubMed ID: 18551609
    [Abstract] [Full Text] [Related]

  • 14. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N.
    J Viral Hepat; 2010 Mar 01; 17(3):185-91. PubMed ID: 19709362
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2008 Aug 01; 80(8):1363-9. PubMed ID: 18551610
    [Abstract] [Full Text] [Related]

  • 16. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.
    Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H.
    J Med Virol; 2010 Jan 01; 82(1):41-8. PubMed ID: 19950230
    [Abstract] [Full Text] [Related]

  • 17. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2009 Jun 01; 81(6):1032-9. PubMed ID: 19382270
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2006 Jan 01; 78(1):83-90. PubMed ID: 16299715
    [Abstract] [Full Text] [Related]

  • 19. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Miyasaka A, Kumagai I, Abe K, Suzuki K.
    Hepatogastroenterology; 2012 May 01; 59(115):794-9. PubMed ID: 22020909
    [Abstract] [Full Text] [Related]

  • 20. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, Kanazawa N, Itakura J, Miyake S, Sakai T.
    Hepatology; 2001 Aug 01; 34(2):377-84. PubMed ID: 11481623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.